Lexeo Therapeutics partners with Apertura Gene Therapy for TfR1 CapX access in Friedreich ataxia program

Bitget2026/09/23 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lexeo Therapeutics entered an agreement with Apertura Gene Therapy for access to TfR1 CapX for a Friedreich ataxia gene-therapy program.
TfR1 CapX is an intravenously delivered AAV capsid designed to target hTfR1 and cross the blood-brain barrier.
Lexeo plans to evaluate a less invasive CNS delivery route following initial systemic administration of LX2006.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY54973) on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lexeo Therapeutics partners with Apertura Gene Therapy for TfR1 CapX access in Friedreich ataxia program

You may also like

Crypto prices